Back to today’s briefing

Story perspectives

Roche and Sanofi Report Earnings, Highlight Growth Strategies

1/29/2026

49 10

Summary

Story summary

On January 29, 2026, Roche and Sanofi reported earnings that met expectations.
Roche's adjusted operating income rose 5% in 2025, driven by Ocrevus and Hemlibra, but fell short of market consensus.
Roche expects mid-single-digit sales growth for 2026.
Sanofi's fourth-quarter sales grew 13%, supported by new medicines and Dupixent.
Roche is investing in obesity treatments, with CT-388 showing a 22.5% weight reduction in Phase 2.

1 of 1

Story summary

On January 29, 2026, Roche and Sanofi reported earnings that met expectations.
Roche's adjusted operating income rose 5% in 2025, driven by Ocrevus and Hemlibra, but fell short of market consensus.
Roche expects mid-single-digit sales growth for 2026.
Sanofi's fourth-quarter sales grew 13%, supported by new medicines and Dupixent.
Roche is investing in obesity treatments, with CT-388 showing a 22.5% weight reduction in Phase 2.